Most processors decline peptide merchants on sight. This guide covers domestic vs offshore options, FDA/DEA compliance, COA requirements, and multi-rail architecture for BPC-157, TB-500, SARM, and research peptide businesses.
Research peptide merchants face the highest debanking rate of any e-commerce vertical. Stripe, PayPal, and Square categorically decline the category. Many high-risk processors that accept CBD, firearms, or nutraceuticals still refuse peptides because of FDA and DEA enforcement risk around specific compounds like BPC-157, semaglutide analogues, and certain SARMs.
Peptides occupy a regulatory gray area that makes acquiring banks uncomfortable. The products are not explicitly illegal to sell for research purposes, but the FDA has issued warning letters to companies selling BPC-157 and other peptides with implied human-use claims. The DEA has investigated peptide vendors whose marketing crosses the line from research supply to consumer health product.
The FDA has intensified enforcement around research peptides, particularly BPC-157. In late 2024, the FDA categorized BPC-157 as a bulk drug substance that cannot be compounded under section 503A or 503B. For research suppliers operating under RUO framing, the direct legal impact is limited — but the indirect effect on payment processing has been severe. Processors see the headlines and paint the entire category with the same brush.
"Underwriters do not always distinguish between a compounding pharmacy selling to patients and a research supplier selling to labs. The burden falls on the merchant to demonstrate compliant RUO positioning."
Research Use Only labeling is the compliance framework that makes peptide payment processing possible. Every element of your business must consistently frame products as research reagents, not consumer health products.
Most established peptide merchants need both domestic and offshore processing. Domestic acquirers offer lower rates (3.5-5%) and faster settlement but have stricter documentation requirements and lower chargeback tolerance. Offshore acquirers in Cyprus, Malta, Gibraltar, and certain Caribbean jurisdictions have broader risk appetites for research chemicals — rates run 4-7% with slower settlement, but the relationship is more stable against US FDA enforcement shifts.
The Merchant Category Code assigned to your account determines how card networks monitor your transactions. Peptide merchants typically use MCC 5047 (Laboratory/Scientific Supplies), MCC 5122 (Drugs, Drug Proprietaries, and Sundries), or MCC 5999 (Miscellaneous Specialty Retail). Misclassifying your MCC can result in compliance actions, MATCH listing, or termination.
No peptide merchant should depend on a single processor. A multi-rail approach distributes risk across offshore card processing (primary), domestic ACH/eCheck (secondary), cryptocurrency acceptance (tertiary), and domestic card processing where available (backup). This architecture ensures a single termination never kills your revenue.
If your account was closed and you believe the termination was unjustified, you can file a complaint with the Consumer Financial Protection Bureau. The CFPB has taken active interest in debanking since 2024, particularly for businesses operating legally. Filing creates a paper trail and may prompt the institution to review its decision.
Cybin Enterprises has placed research peptide merchants across BPC-157, TB-500, SARM, and general research chemical catalogs. We know which processors actively underwrite the RUO category, what documentation they require, and how to structure applications for approval. Our consultation is free — call (412) 218-3006 or submit a consultation request to get started.
Yes. Peptide merchants need specialist processors that explicitly underwrite the RUO (Research Use Only) category. Mainstream processors like Stripe, PayPal, and Square decline peptide merchants as a matter of policy. We work with domestic and offshore acquiring banks that understand the research chemical vertical.
Certificates of Analysis (COAs) for all products, RUO labeling documentation, supplier agreements, business formation documents, bank statements (3-6 months), processing history if available, and a compliant website with 'not for human consumption' disclosures throughout.
Standard approvals take 5-14 business days from a complete application. Domestic processors with RUO experience can sometimes approve in 5-7 business days. Offshore relationships or merchants with prior terminations may take 2-3 weeks.
Not always, but most benefit from a multi-rail approach that includes offshore card processing, domestic ACH, and optionally cryptocurrency. Offshore acquirers have broader risk appetites for research chemicals and are less reactive to US FDA enforcement actions.
Cybin Enterprises is a payment services intermediary specializing in high-risk merchant accounts. Our team brings decades of experience in payment processing, compliance, and risk management.
Expertise: High-risk underwriting, payment compliance, chargeback management, multi-processor routing
Understanding the factors that classify a business as high-risk is the first step to securing stable payment processing.
Chargeback disputes can threaten your merchant account. Discover how early dispute alert systems help merchants resolve issues before they escalate.
Whether you're dealing with account termination or launching a new high-risk business, we can help you secure stable payment processing.
